{"id":"nitazoxanide","rwe":[{"pmid":"41901747","year":"2026","title":"Promising Drug Repurposing Candidates Targeting Free-Living Amoebae: A Systematic and Critical Review of Laboratory-Based Evidence.","finding":"","journal":"Pathogens (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41888548","year":"2026","title":"Proteasome inhibition promotes Foxn1 expression in thymic epithelial cells and induces thymic regeneration in mice.","finding":"","journal":"Cell death and differentiation","studyType":"Clinical Study"},{"pmid":"41888416","year":"2026","title":"Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis.","finding":"","journal":"Naunyn-Schmiedeberg's archives of pharmacology","studyType":"Clinical Study"},{"pmid":"41867367","year":"2025","title":"Nitazoxanide reduced inflammatory markers and mitochondrial changes in human retinal endothelial cells grown in high glucose.","finding":"","journal":"Molecular vision","studyType":"Clinical Study"},{"pmid":"41823635","year":"2025","title":"Chronic persistent Norovirus in the immune-compromised host.","finding":"","journal":"Current opinion in infectious diseases","studyType":"Clinical Study"}],"_fda":{"id":"4729e7ee-3333-ee2b-e063-6394a90aa85c","set_id":"295011e1-f919-4e5a-b9e7-4c784f623a86","openfda":{"nui":["N0000175485"],"upc":["0331722100311"],"unii":["SOA12P041N"],"route":["ORAL"],"rxcui":["427163"],"spl_id":["4729e7ee-3333-ee2b-e063-6394a90aa85c"],"brand_name":["Nitazoxanide"],"spl_set_id":["295011e1-f919-4e5a-b9e7-4c784f623a86"],"package_ndc":["31722-100-31","31722-100-30","31722-100-32"],"product_ndc":["31722-100"],"generic_name":["NITAZOXANIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["NITAZOXANIDE"],"pharm_class_epc":["Antiprotozoal [EPC]"],"manufacturer_name":["Camber Pharmaceuticals, Inc."],"application_number":["ANDA218701"],"is_original_packager":[true]},"version":"1","pregnancy":["8.1 Pregnancy Risk Summary There are no data with nitazoxanide in pregnant women to inform a drug-associated risk. No teratogenicity or fetotoxicity was observed in animal reproduction studies with administration of nitazoxanide to pregnant rats and rabbits during organogenesis at exposures 30 and 2 times, respectively, the exposure at the maximum recommended human dose of 500 mg twice daily based on body surface area (BSA). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Nitazoxanide was administered orally to pregnant rats at doses of 0, 200, 800 or 3200 mg/kg/day on gestation days 6 to 15. Nitazoxanide produced no evidence of systemic maternal toxicity when administered once daily via oral gavage to pregnant female rats at levels up to 3200 mg/kg/day during the period of organogenesis. In rabbits, nitazoxanide was administered at doses of 0, 25, 50, or 100 mg/kg/day on gestation days 7 to 20. Oral treatment of pregnant rabbits with nitazoxanide during organogenesis resulted in minimal maternal toxicity and no external fetal anomalies."],"overdosage":["10 OVERDOSAGE Limited information on nitazoxanide overdosage is available. In the event of overdose, gastric lavage may be appropriate soon after oral administration. Patients should be observed and given symptomatic and supportive treatment. There is no specific antidote for overdose with nitazoxanide. Because tizoxanide is highly protein bound (>99.9%), dialysis is unlikely to significantly reduce plasma concentrations of the drug."],"description":["11 DESCRIPTION Nitazoxanide tablets contain the active ingredient, nitazoxanide, a synthetic antiprotozoal for oral administration. Nitazoxanide is off-white to yellow powder. It is practically insoluble in ethanol, water and soluble in N, N-dimethylacetamide. Chemically, nitazoxanide is 2-((5-Nitrothiazol-2-yl) carbamoyl) phenyl acetate. The molecular formula is C 12 H 9 N 3 O 5 S and the molecular weight is 307.28. The structural formula is: Nitazoxanide tablets contain 500 mg of nitazoxanide and the following inactive ingredients: corn starch, D&C yellow #10 aluminum lake, FD&C blue #2, FD&C yellow #6, hypromellose, lecithin (soya), magnesium stearate, polyvinyl alcohol, pregelatinized starch, sodium starch glycolate, talc, titanium dioxide and xanthan gum. nitazoxanidetabletsstructure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 Nitazoxanide Tablets (500 mg) Nitazoxanide tablets 500 mg are green colored, round biconvex film-coated tablets debossed with “V1” on one side and “1” on the other side. Each tablet contains 500 mg of nitazoxanide. The tablets are packaged in HDPE bottles of 6, 12 and 30 tablets. Bottles of 12 tablets NDC 31722-100-31 Bottles of 30 tablets NDC 31722-100-30 Bottles of 6 tablets NDC 31722-100-32 Store the tablets at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]"],"geriatric_use":["8.5 Geriatric Use Clinical studies of nitazoxanide tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing nitazoxanide tablets."],"pediatric_use":["8.4 Pediatric Use The safety and efficacy of nitazoxanide tablets for the treatment of diarrhea caused by G. lamblia or C. parvum in pediatric patients 12 to 17 years of age has been established based on three (3) randomized controlled studies with 47 pediatric subjects treated with nitazoxanide tablets 500 mg. A single nitazoxanide tablet contains a greater amount of nitazoxanide than is recommended for use in pediatric patients 11 years or younger. [see Dosage and Administration ( 2.1 )] ."],"effective_time":"20251230","clinical_studies":["14 CLINICAL STUDIES 14.1 Diarrhea Caused by G. lamblia Diarrhea caused by G. lamblia in adults and adolescents 12 years of age or older: In a double-blind, controlled trial (Study 1) conducted in Peru and Egypt in adults and adolescents with diarrhea and with one or more enteric symptoms (e.g., abdominal pain, nausea, vomiting, fever, abdominal distention, loss of appetite, flatulence) caused by G. lamblia , a three-day course of treatment with nitazoxanide tablets administered 500 mg twice daily was compared with a placebo tablet for 3 days. A second double-blind, controlled trial (Study 2) conducted in Egypt in adults and adolescents with diarrhea and with or without enteric symptoms (e.g., abdominal colic, abdominal tenderness, abdominal cramps, abdominal distention, fever, bloody stool) caused by G. lamblia compared nitazoxanide tablets administered 500 mg twice daily for 3 days to a placebo tablet. For both of these studies, clinical response was evaluated 4 to 7 days following the end of treatment. A clinical response of ‘well’ was defined as ‘no symptoms, no watery stools and no more than 2 soft stools with no hematochezia within the past 24 hours’ or ‘no symptoms and no unformed stools within the past 48 hours.’ The following clinical response rates were obtained: Table 4. Adult and Adolescent Patients with Diarrhea Caused by G. lamblia Clinical Response Rates* 4 to 7 Days Post-therapy % (Number of Successes/Total) Nitazoxanide Tablets Placebo Tablets Study 1 85% (46/54) ¶ § 44% (12/27) Study 2 100% (8/8) 30% (3/10) * Includes all patients randomized with G. lamblia as the sole pathogen. Patients failing to complete the studies were treated as failures. ¶ Clinical response rates statistically significantly higher when compared to placebo. § The 95% confidence interval of the difference in response rates for the tablet and suspension is (-14%, 17%). Some patients with ‘well’ clinical responses had G. lamblia cysts in their stool samples 4 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment. 14.2 Diarrhea Caused by C. parvum Diarrhea caused by C. parvum in adults and adolescents 12 years of age or older: In a double-blind, controlled trial conducted in Egypt in adults and adolescents with diarrhea and with or without enteric symptoms (e.g., abdominal pain/cramps, nausea, vomiting) caused by C. parvum , a three-day course of treatment with nitazoxanide tablets administered 500 mg twice daily was compared with a placebo tablet for 3 days. Clinical response was evaluated 4 to 7 days following the end of treatment. A clinical response of ‘well’ was defined as ‘no symptoms, no watery stools and no more than 2 soft stools within the past 24 hours’ or ‘no symptoms and no unformed stools within the past 48 hours.’ The following clinical response rates were obtained: Table 6. Clinical Response Rates in Adult and Adolescent Patients 4 to 7 Days Post-therapy % (Number of Successes/Total) Nitazoxanide Tablets Placebo Tablets Intent-to-treat analysis * 96% (27/28) ¶ § 41% (11/27) * Includes all patients randomized with C. parvum as the sole pathogen. Patients failing to complete the study were treated as failures. ¶ Clinical response rates statistically significantly higher when compared to placebo. § The 95% confidence interval of the difference in response rates for the tablet and suspension is (-10%, 28%). In a second double-blind, placebo-controlled trial of nitazoxanide tablets conducted in Egypt in adults and adolescents with diarrhea and with or without enteric symptoms (e.g., abdominal colic, abdominal cramps, epigastric pain) caused by C. parvum as the sole pathogen, clinical and parasitological response rates showed a similar trend to the first study. Clinical response rates, evaluated 2 to 6 days following the end of treatment, were 71% (15/21) in the nitazoxanide group and 42.9% (9/21) in the placebo group. Some patients with ‘well’ clinical responses had C. parvum oocysts in their stool samples 4 to 7 days following the end of treatment. The relevance of stool examination results in these patients is unknown. Patients should be managed based upon clinical response to treatment."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Single Dosing: Following oral administration of nitazoxanide tablets, the parent drug, nitazoxanide, is not detected in plasma. The pharmacokinetic parameters of the metabolites, tizoxanide and tizoxanide glucuronide are shown in Tables 2 and 3 below. Table 2. Mean (± SD) plasma pharmacokinetic parameters of tizoxanide and tizoxanide glucuronide following administration of a single dose of one 500 mg nitazoxanide tablet with food to subjects ≥12 years of age Tizoxanide Tizoxanide Glucuronide Age C max (mcg/mL) *T max (hr) AUC τ (mcg•hr/mL) C max (mcg/mL) *T max (hr) AUC τ (mcg•hr/mL) 12 to 7 years 9.1 (6.1) 4.0 (1 to 4) 39.5 (24.2) 7.3 (1.9) 4.0 (2 to 8) 46.5 (18.2) ≥18 years 10.6 (2.0) 3.0 (2 to 4) 41.9 (6.0) 10.5 (1.4) 4.5 (4 to 6) 63.0 (12.3) * T max is given as a Mean (Range) Multiple dosing: Following oral administration of a single nitazoxanide tablet every 12 hours for 7 consecutive days, there was no significant accumulation of nitazoxanide metabolites tizoxanide or tizoxanide glucuronide detected in plasma. Bioavailability: Alina for oral suspension is not bioequivalent to nitazoxanide tablets. The relative bioavailability of the suspension compared to the tablet was 70%. When nitazoxanide tablets are administered with food, the AUC τ of tizoxanide and tizoxanide glucuronide in plasma is increased almost two-fold and the C max is increased by almost 50%. Nitazoxanide tablets were administered with food in clinical trials and hence they are recommended to be administered with food [see Dosage and Administration ( 2.1 )] . Distribution In plasma, more than 99% of tizoxanide is bound to proteins. Elimination Metabolism Following oral administration in humans, nitazoxanide is rapidly hydrolyzed to an active metabolite, tizoxanide (desacetyl-nitazoxanide). Tizoxanide then undergoes conjugation, primarily by glucuronidation. Excretion Tizoxanide is excreted in the urine, bile and feces, and tizoxanide glucuronide is excreted in urine and bile. Approximately two-thirds of the oral dose of nitazoxanide is excreted in the feces and one-third in the urine. Specific Populations Pediatric Patients The pharmacokinetics of tizoxanide and tizoxanide glucuronide following administration of nitazoxanide tablets in pediatric patients 12 to 17 years of age are provided above in Table 2. Mean (±SD) plasma pharmacokinetic parameters of tizoxanide and tizoxanide glcuronide following administration of a single dose of one 500 mg nitazoxanide tablet with food to subject ≥12 years of age. Drug Interaction Studies In vitro studies demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions in ≥2% of patients were abdominal pain, headache, chromaturia, and nausea ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Annora Pharma Private Limited at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of nitazoxanide was evaluated in 2177 HIV-uninfected subjects 12 months of age and older who received nitazoxanide tablets or Alina for oral suspension at the recommended dose for at least three days. In pooled controlled clinical trials involving 536 HIV-uninfected subjects treated with nitazoxanide tablets or Alina for oral suspension, the most common adverse reactions were abdominal pain, headache, chromaturia and nausea (≥2%). Safety data were analyzed separately for 280 HIV-uninfected subjects ≥12 years of age receiving nitazoxanide at the recommended dose for at least three days in 5 placebo-controlled clinical trials and for 256 HIV-uninfected subjects 1 through 11 years of age in 7 controlled clinical trials. There were no differences between the adverse reactions reported for nitazoxanide-treated subjects based upon age. 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of nitazoxanide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following is a list of adverse reactions spontaneously reported with nitazoxanide tablets which were not included in clinical trial listings: Gastrointestinal disorders: diarrhea, gastroesophageal reflux disease Nervous System disorders: dizziness Respiratory, thoracic and mediastinal disorders: dyspnea Skin and subcutaneous tissue disorders: rash, urticaria"],"contraindications":["4 CONTRAINDICATIONS Hypersensitivity ( 4.1 ) 4.1 Hypersensitivity Nitazoxanide tablets are contraindicated in patients with a prior hypersensitivity to nitazoxanide or any other ingredient in the formulations."],"drug_interactions":["7 DRUG INTERACTIONS Competition for binding sites may occur when administered concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices. Monitor for adverse reactions ( 7 ). 7.1 Highly Protein Bound Drugs with Narrow Therapeutic Indices Tizoxanide (the active metabolite of nitazoxanide) is highly bound to plasma protein (>99.9%). Therefore, monitor for adverse reactions when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin)."],"labor_and_delivery":["8.2 Lactation Risk Summary No information regarding the presence of nitazoxanide in human milk, the effects on the breastfed infant, or the effects on milk production is available. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for nitazoxanide and any potential adverse effects on the breastfed infant from nitazoxanide or from the underlying maternal condition."],"mechanism_of_action":["12.1 Mechanism of Action Nitazoxanide is an antiprotozoal [see Microbiology ( 12.4 )]."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Nitazoxanide is an antiprotozoal [see Microbiology ( 12.4 )]. 12.3 Pharmacokinetics Absorption Single Dosing: Following oral administration of nitazoxanide tablets, the parent drug, nitazoxanide, is not detected in plasma. The pharmacokinetic parameters of the metabolites, tizoxanide and tizoxanide glucuronide are shown in Tables 2 and 3 below. Table 2. Mean (± SD) plasma pharmacokinetic parameters of tizoxanide and tizoxanide glucuronide following administration of a single dose of one 500 mg nitazoxanide tablet with food to subjects ≥12 years of age Tizoxanide Tizoxanide Glucuronide Age C max (mcg/mL) *T max (hr) AUC τ (mcg•hr/mL) C max (mcg/mL) *T max (hr) AUC τ (mcg•hr/mL) 12 to 7 years 9.1 (6.1) 4.0 (1 to 4) 39.5 (24.2) 7.3 (1.9) 4.0 (2 to 8) 46.5 (18.2) ≥18 years 10.6 (2.0) 3.0 (2 to 4) 41.9 (6.0) 10.5 (1.4) 4.5 (4 to 6) 63.0 (12.3) * T max is given as a Mean (Range) Multiple dosing: Following oral administration of a single nitazoxanide tablet every 12 hours for 7 consecutive days, there was no significant accumulation of nitazoxanide metabolites tizoxanide or tizoxanide glucuronide detected in plasma. Bioavailability: Alina for oral suspension is not bioequivalent to nitazoxanide tablets. The relative bioavailability of the suspension compared to the tablet was 70%. When nitazoxanide tablets are administered with food, the AUC τ of tizoxanide and tizoxanide glucuronide in plasma is increased almost two-fold and the C max is increased by almost 50%. Nitazoxanide tablets were administered with food in clinical trials and hence they are recommended to be administered with food [see Dosage and Administration ( 2.1 )] . Distribution In plasma, more than 99% of tizoxanide is bound to proteins. Elimination Metabolism Following oral administration in humans, nitazoxanide is rapidly hydrolyzed to an active metabolite, tizoxanide (desacetyl-nitazoxanide). Tizoxanide then undergoes conjugation, primarily by glucuronidation. Excretion Tizoxanide is excreted in the urine, bile and feces, and tizoxanide glucuronide is excreted in urine and bile. Approximately two-thirds of the oral dose of nitazoxanide is excreted in the feces and one-third in the urine. Specific Populations Pediatric Patients The pharmacokinetics of tizoxanide and tizoxanide glucuronide following administration of nitazoxanide tablets in pediatric patients 12 to 17 years of age are provided above in Table 2. Mean (±SD) plasma pharmacokinetic parameters of tizoxanide and tizoxanide glcuronide following administration of a single dose of one 500 mg nitazoxanide tablet with food to subject ≥12 years of age. Drug Interaction Studies In vitro studies demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes. 12.4 Microbiology Mechanism of Action The antiprotozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic energy metabolism. Studies have shown that the PFOR enzyme from G. lamblia directly reduces nitazoxanide by transfer of electrons in the absence of ferredoxin. The DNA-derived PFOR protein sequence of C. parvum appears to be similar to that of G. lamblia . Interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity. Resistance A potential for development of resistance by C. parvum or G. lamblia to nitazoxanide has not been examined. Antimicrobial Activity Nitazoxanide and its metabolite, tizoxanide, are active in vitro in inhibiting the growth of (i) sporozoites and oocysts of C. parvum and (ii) trophozoites of G. lamblia. Susceptibility Test Methods For protozoa such as C. parvum and G. lamblia , standardized tests for use in clinical microbiology laboratories are not available."],"indications_and_usage":["1 INDICATIONS AND USAGE Diarrhea caused by Giardia lamblia or Cryptosporidium parvum: Nitazoxanide tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum . Limitations of Use Nitazoxanide tablets have not been shown to be effective for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients [see Clinical Studies (14.2) ] . Nitazoxanide tablets are antiprotozoal indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum (1 ). Limitations of Use: Nitazoxanide tablets have not been shown to be effective for the treatment of diarrhea caused by C. parvum in HIV-infected or immunodeficient patients (1)."],"clinical_studies_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><col width=\"18.7%\"/><col width=\"41.84%\"/><col width=\"39.46%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"/><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Nitazoxanide Tablets</content> </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Placebo Tablets</content> </td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\">Study 1  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">85% (46/54) <sup>&#xB6; &#xA7;</sup> </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">44% (12/27)  </td></tr><tr><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\">Study 2  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">100% (8/8)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">30% (3/10)  </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><col width=\"36.16%\"/><col width=\"36.2%\"/><col width=\"27.64%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"middle\">  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\"><content styleCode=\"bold\">Nitazoxanide Tablets</content> </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\"><content styleCode=\"bold\">Placebo Tablets</content> </td></tr><tr><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Intent-to-treat analysis <sup>*</sup> </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">96% (27/28) <sup>&#xB6; &#xA7;</sup> </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">41% (11/27)  </td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long-term carcinogenicity studies have not been conducted. Mutagenesis Nitazoxanide was not genotoxic in the Chinese hamster ovary (CHO) cell chromosomal aberration assay or the mouse micronucleus assay. Nitazoxanide was genotoxic in one tester strain (TA 100) in the Ames bacterial mutation assay. Impairment of Fertility Nitazoxanide did not adversely affect male or female fertility in the rat at 2400 mg/kg/day (approximately 20 times the clinical adult dose adjusted for body surface area)."],"pharmacokinetics_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><col width=\"14.82%\"/><col width=\"17.54%\"/><col width=\"12.84%\"/><col width=\"15.12%\"/><col width=\"11.72%\"/><col width=\"12.84%\"/><col width=\"15.12%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"/><td colspan=\"3\" align=\"center\" styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Tizoxanide</content> </td><td colspan=\"3\" align=\"center\" styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Tizoxanide Glucuronide</content> </td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Age  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">C <sub>max</sub>(mcg/mL)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">*T <sub>max</sub>  (hr)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">AUC <sub>&#x3C4;</sub>  (mcg&#x2022;hr/mL)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">C <sub>max</sub>  (mcg/mL)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">*T <sub>max</sub>  (hr)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">AUC <sub>&#x3C4;</sub>  (mcg&#x2022;hr/mL)  </td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">12 to 7 years  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">9.1 (6.1)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">4.0 (1 to 4)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">39.5 (24.2)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">7.3 (1.9)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">4.0 (2 to 8)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">46.5 (18.2)  </td></tr><tr><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">&#x2265;18 years  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">10.6 (2.0)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">3.0 (2 to 4)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">41.9 (6.0)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">10.5 (1.4)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">4.5 (4 to 6)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">63.0 (12.3)  </td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise patients and parents/caregivers of pediatric patients taking nitazoxanide tablets of the following information: Dosage and Administration: Nitazoxanide tablets should be taken with food. Drug-drug Interactions: Avoid concurrent warfarin use. Manufactured for: Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 By: Annora Pharma Pvt. Ltd. Sangareddy - 502313, Telangana, India. Revised: 05/2025 camberlogo"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION • Nitazoxanide tablets should not be administered to pediatric patient 11 years of age or younger ( 2.1 ). • Dosage for treatment of diarrhea caused by G.lamblia or C. parvum ( 2.1 ): Age Dosage Duration 12 years and older One 500 mg nitazoxanide tablet every 12 hours with food 3 days 2.1 Recommended Dosage and Important Administration Instructions Important Administration Instructions for Pediatric Patients 11 years of Age or Younger: Nitazoxanide tablets should not be administered to pediatric patients 11 years of age or younger because a single tablet contains a greater amount of nitazoxanide than the recommended dosing in this pediatric age group. Table 1. Recommended Dosage Age Dosage Duration 12 years and older One 500 mg nitazoxanide tablet taken orally every 12 hours with food 3 days"],"spl_product_data_elements":["Nitazoxanide Nitazoxanide STARCH, CORN D&C YELLOW NO. 10 ALUMINUM LAKE FD&C BLUE NO. 2 FD&C YELLOW NO. 6 HYPROMELLOSE 2910 (15 MPA.S) SOYBEAN LECITHIN MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED SODIUM STARCH GLYCOLATE TYPE A POTATO TALC TITANIUM DIOXIDE XANTHAN GUM NITAZOXANIDE NITAZOXANIDE biconvex V1;1"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Nitazoxanide tablets: 500 mg ( 3 ). 3.1 Nitazoxanide Tablets (500 mg) Green colored, round biconvex film-coated tablets debossed with “V1” on one side and “1” on the other side. Each tablet contains 500 mg of nitazoxanide."],"clinical_pharmacology_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><col width=\"14.82%\"/><col width=\"17.54%\"/><col width=\"12.84%\"/><col width=\"15.12%\"/><col width=\"11.72%\"/><col width=\"12.84%\"/><col width=\"15.12%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"/><td colspan=\"3\" align=\"center\" styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Tizoxanide</content> </td><td colspan=\"3\" align=\"center\" styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Tizoxanide Glucuronide</content> </td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">Age  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">C <sub>max</sub>(mcg/mL)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">*T <sub>max</sub>  (hr)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">AUC <sub>&#x3C4;</sub>  (mcg&#x2022;hr/mL)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">C <sub>max</sub>  (mcg/mL)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">*T <sub>max</sub>  (hr)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">AUC <sub>&#x3C4;</sub>  (mcg&#x2022;hr/mL)  </td></tr><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">12 to 7 years  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">9.1 (6.1)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">4.0 (1 to 4)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">39.5 (24.2)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">7.3 (1.9)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">4.0 (2 to 8)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">46.5 (18.2)  </td></tr><tr><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"middle\">&#x2265;18 years  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">10.6 (2.0)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">3.0 (2 to 4)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">41.9 (6.0)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">10.5 (1.4)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">4.5 (4 to 6)  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"middle\">63.0 (12.3)  </td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no data with nitazoxanide in pregnant women to inform a drug-associated risk. No teratogenicity or fetotoxicity was observed in animal reproduction studies with administration of nitazoxanide to pregnant rats and rabbits during organogenesis at exposures 30 and 2 times, respectively, the exposure at the maximum recommended human dose of 500 mg twice daily based on body surface area (BSA). In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Nitazoxanide was administered orally to pregnant rats at doses of 0, 200, 800 or 3200 mg/kg/day on gestation days 6 to 15. Nitazoxanide produced no evidence of systemic maternal toxicity when administered once daily via oral gavage to pregnant female rats at levels up to 3200 mg/kg/day during the period of organogenesis. In rabbits, nitazoxanide was administered at doses of 0, 25, 50, or 100 mg/kg/day on gestation days 7 to 20. Oral treatment of pregnant rabbits with nitazoxanide during organogenesis resulted in minimal maternal toxicity and no external fetal anomalies. 8.2 Lactation Risk Summary No information regarding the presence of nitazoxanide in human milk, the effects on the breastfed infant, or the effects on milk production is available. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for nitazoxanide and any potential adverse effects on the breastfed infant from nitazoxanide or from the underlying maternal condition. 8.4 Pediatric Use The safety and efficacy of nitazoxanide tablets for the treatment of diarrhea caused by G. lamblia or C. parvum in pediatric patients 12 to 17 years of age has been established based on three (3) randomized controlled studies with 47 pediatric subjects treated with nitazoxanide tablets 500 mg. A single nitazoxanide tablet contains a greater amount of nitazoxanide than is recommended for use in pediatric patients 11 years or younger. [see Dosage and Administration ( 2.1 )] . 8.5 Geriatric Use Clinical studies of nitazoxanide tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing nitazoxanide tablets. 8.6 Renal and Hepatic Impairment The pharmacokinetics of nitazoxanide in patients with compromised renal or hepatic function has not been studied. 8.7 HIV-Infected or Immunodeficient Patients Nitazoxanide tablets have not been studied for the treatment of diarrhea caused by G. lamblia in HIV-infected or immunodeficient patients. Nitazoxanide tablets have not been shown to be superior to placebo for the treatment of diarrhea caused by C. parvum in HIV-infected or immunodeficient patients [see Clinical Studies ( 14 )] ."],"dosage_and_administration_table":["<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><col width=\"20%\"/><col width=\"58%\"/><col width=\"21%\"/><tbody><tr styleCode=\"Botrule\"><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Age</content> </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Dosage</content> </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Duration</content> </td></tr><tr><td align=\"center\" styleCode=\"Lrule Rrule\" valign=\"top\">12 years and older  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">One 500 mg nitazoxanide tablet every 12 hours with food  </td><td align=\"center\" styleCode=\"Rrule\" valign=\"top\">3 days  </td></tr></tbody></table>","<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" width=\"100%\"><col width=\"21%\"/><col width=\"67%\"/><col width=\"11%\"/><tbody><tr styleCode=\"Botrule\"><td styleCode=\"Lrule Rrule\" valign=\"top\"><content styleCode=\"bold\">Age</content> </td><td styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Dosage</content> </td><td styleCode=\"Rrule\" valign=\"top\"><content styleCode=\"bold\">Duration</content> </td></tr><tr><td styleCode=\"Lrule Rrule\" valign=\"top\">12 years and older  </td><td styleCode=\"Rrule\" valign=\"top\">One 500 mg nitazoxanide tablet taken orally every 12 hours with food  </td><td styleCode=\"Rrule\" valign=\"top\">3 days  </td></tr></tbody></table>"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Nitazoxanide Tablets- 12's Container Label Nitazoxanide Tablets- 12s Carton Label Nitazoxanide Tablets- 30's Container Label Nitazoxanide Tablets- 30's Carton Label nitazoxanidetablets12scontainerlabel nitazoxanidetablets12scartonlabel nitazoxanidetablets30scontainerlabel nitazoxanidetablets30scartonlabel"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Long-term carcinogenicity studies have not been conducted. Mutagenesis Nitazoxanide was not genotoxic in the Chinese hamster ovary (CHO) cell chromosomal aberration assay or the mouse micronucleus assay. Nitazoxanide was genotoxic in one tester strain (TA 100) in the Ames bacterial mutation assay. Impairment of Fertility Nitazoxanide did not adversely affect male or female fertility in the rat at 2400 mg/kg/day (approximately 20 times the clinical adult dose adjusted for body surface area)."]},"tags":[{"label":"Antiprotozoal","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Anoctamin-1","category":"target"},{"label":"ANO1","category":"gene"},{"label":"AKR1B1","category":"gene"},{"label":"STAT3","category":"gene"},{"label":"P01AX11","category":"atc"},{"label":"Oral","category":"route"},{"label":"Powder","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Giardiasis","category":"indication"},{"label":"Infection by Cryptosporidium","category":"indication"},{"label":"Romark","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"62 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"55 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"46 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"45 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"39 reports"},{"date":"","signal":"THERAPEUTIC PRODUCT EFFECT INCOMPLETE","source":"FDA FAERS","actionTaken":"32 reports"},{"date":"","signal":"CHEST PAIN","source":"FDA FAERS","actionTaken":"31 reports"},{"date":"","signal":"COMA SCALE ABNORMAL","source":"FDA FAERS","actionTaken":"31 reports"},{"date":"","signal":"MICROSPORIDIA INFECTION","source":"FDA FAERS","actionTaken":"31 reports"},{"date":"","signal":"PNEUMOCYSTIS JIROVECII INFECTION","source":"FDA FAERS","actionTaken":"31 reports"}],"commonSideEffects":[{"effect":"abdominal pain","drugRate":"≥2%","severity":"common","_validated":true},{"effect":"headache","drugRate":"≥2%","severity":"common","_validated":true},{"effect":"chromaturia","drugRate":"≥2%","severity":"common","_validated":true},{"effect":"nausea","drugRate":"≥2%","severity":"common","_validated":true},{"effect":"diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"gastroesophageal reflux disease","drugRate":"reported","severity":"unknown"},{"effect":"dizziness","drugRate":"reported","severity":"unknown"},{"effect":"dyspnea","drugRate":"reported","severity":"unknown"},{"effect":"rash","drugRate":"reported","severity":"unknown"},{"effect":"urticaria","drugRate":"reported","severity":"unknown"}],"contraindications":["Diabetes mellitus","Disease of liver","Kidney disease"],"specialPopulations":{"Pregnancy":"There are no data with nitazoxanide in pregnant women to inform drug-associated risk. No teratogenicity or fetotoxicity was observed in animal reproduction studies with administration of nitazoxanide to pregnant rats and rabbits during organogenesis at exposure 30 and times, respectively, the exposure at the maximum recommended human dose of 500 mg twice daily based on body surface area (BSA).In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.","Geriatric use":"Clinical studies of nitazoxanide tablets and Alinia for oral suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing nitazoxanide tablets and Alinia for oral suspension.","Paediatric use":"The safety and efficacy of Nitazoxanide Tablets for the treatment of diarrhea caused by G. lamblia or C. parvum in pediatric patients 12 to 17 years of age has been established based on three (3) randomized, controlled studies with 47 pediatric subjects treated with Nitazoxanide Tablets see Clinical Studies (14)]. single Nitazoxanide Tablet contains greater amount of nitazoxanide than is recommended for use in pediatric patients 11 years or younger."}},"trials":[],"aliases":[],"company":"Romark","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$98.1078/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$35,809","description":"NITAZOXANIDE 500 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=NITAZOXANIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:08:42.049617+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:08:48.511165+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:08:40.686308+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NITAZOXANIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:08:49.552007+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:08:39.730435+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:08:39.730496+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:08:39.730510+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:08:51.064227+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Pyruvate:ferredoxin oxidoreductase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:08:50.161194+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1401/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:08:50.057290+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA218701","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:08:39.730518+00:00"}},"allNames":"alinia","offLabel":[],"synonyms":["nitazoxanide","nitazode","nitazoxanida","nizonide"],"timeline":[{"date":"2002-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ROMARK to Romark"},{"date":"2002-11-22","type":"positive","source":"DrugCentral","milestone":"FDA approval (Romark)"},{"date":"2025-04-15","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"approvals":[{"date":"2002-11-22","orphan":true,"company":"ROMARK","regulator":"FDA"}],"brandName":"Alinia","ecosystem":[{"indication":"Giardiasis","otherDrugs":[{"name":"metronidazole","slug":"metronidazole","company":"Gd Searle Llc"},{"name":"secnidazole","slug":"secnidazole","company":"Symbiomix Therapeutics Llc"},{"name":"tinidazole","slug":"tinidazole","company":"Mission Pharma"}],"globalPrevalence":null},{"indication":"Infection by Cryptosporidium","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Anoctamin-1","novelty":"Follow-on","targets":[{"gene":"ANO1","source":"DrugCentral","target":"Anoctamin-1","protein":"Anoctamin-1"},{"gene":"AKR1B1","source":"DrugCentral","target":"Aldose reductase","protein":"Aldose reductase"},{"gene":"STAT3","source":"DrugCentral","target":"Signal transducer and activator of transcription 3","protein":"Signal transducer and activator of transcription 3"}],"modality":"Small Molecule","drugClass":"Antiprotozoal [EPC]","explanation":"Nitazoxanide is an antiprotozoal see Microbiology (12.4)].","oneSentence":"Alinia works by inhibiting the Anoctamin-1 ion channel, disrupting the parasite's ability to maintain its cellular environment.","technicalDetail":"NITAZOXANIDE acts as a potent inhibitor of the Anoctamin-1 ion channel, which is essential for the parasite's survival. By blocking this channel, NITAZOXANIDE disrupts the parasite's ability to maintain its cellular environment, ultimately leading to its death.","_target_confidence":0.5},"commercial":{"launchDate":"2002","_launchSource":"DrugCentral (FDA 2002-11-22, ROMARK)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1943","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=NITAZOXANIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NITAZOXANIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T14:40:42.289019","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:56.437060+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"atovaquone","drugSlug":"atovaquone","fdaApproval":"1992-11-25","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"trimetrexate","drugSlug":"trimetrexate","fdaApproval":"1993-12-17","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"nitazoxanide","indications":{"approved":[{"name":"Giardiasis","source":"DrugCentral","snomedId":58265007,"regulator":"FDA","eligibility":"patients 12 years and older"},{"name":"Infection by Cryptosporidium","source":"DrugCentral","snomedId":58777003,"regulator":"FDA","eligibility":"patients 12 years and older, excluding HIV-infected or immunodeficient patients"}],"offLabel":[{"name":"Coronavirus infection","source":"DrugCentral","drugName":"NITAZOXANIDE","evidenceCount":91,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Romark","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"atovaquone","brandName":"atovaquone","genericName":"atovaquone","approvalYear":"1992","relationship":"same-class"},{"drugId":"trimetrexate","brandName":"trimetrexate","genericName":"trimetrexate","approvalYear":"1993","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":["COVID-19"],"enrollment":3800,"completionDate":"2027-01"},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":["Mild Cognitive Impairment","Dementia, Mild"],"enrollment":73,"completionDate":"2026-02-09"},{"nctId":"NCT06600711","phase":"PHASE3","title":"Nitazoxanide for Treatment of Cryptosporidium in Children","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2026-04-01","conditions":["Cryptosporidiosis"],"enrollment":480,"completionDate":"2030-05"},{"nctId":"NCT07110441","phase":"PHASE1","title":"Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers","status":"COMPLETED","sponsor":"Genfit","startDate":"2025-08-26","conditions":["Acute-on-Chronic Liver Failure"],"enrollment":52,"completionDate":"2025-12-03"},{"nctId":"NCT04746183","phase":"PHASE1,PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":["Covid19"],"enrollment":600,"completionDate":"2026-07-31"},{"nctId":"NCT04532931","phase":"PHASE2","title":"Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19","status":"COMPLETED","sponsor":"Shin Poong Pharmaceutical Co. Ltd.","startDate":"2020-09-03","conditions":["COVID-19"],"enrollment":192,"completionDate":"2021-08-23"},{"nctId":"NCT07086937","phase":"NA","title":"Efficacy of Nitazoxanide Based Therapy vs Standard Triple Therapy in H-pylori in Children","status":"COMPLETED","sponsor":"Muhammad Aamir Latif","startDate":"2025-01-01","conditions":["Helicobacter Pylori Infection"],"enrollment":66,"completionDate":"2025-06-30"},{"nctId":"NCT05453916","phase":"PHASE1,PHASE2","title":"Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2022-07-01","conditions":["Irritable Bowel Syndrome With Diarrhea"],"enrollment":0,"completionDate":"2024-12-31"},{"nctId":"NCT06993974","phase":"PHASE2","title":"Nitazoxanide in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-05-30","conditions":["Ulcerative Colitis"],"enrollment":70,"completionDate":"2026-12-20"},{"nctId":"NCT03395405","phase":"PHASE2","title":"NNITS-Nitazoxanide for Norovirus in Transplant Patients Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-10-15","conditions":["Gastroenteritis Norovirus"],"enrollment":31,"completionDate":"2021-08-24"},{"nctId":"NCT06827756","phase":"PHASE4","title":"Comparative Study of Secondary Prophylaxis for SBP","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-03-01","conditions":["Spontaneous Bacterial Peritonitis","Cirrhoses, Liver","Ascites"],"enrollment":90,"completionDate":"2022-02-01"},{"nctId":"NCT06817096","phase":"PHASE3","title":"Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza","status":"NOT_YET_RECRUITING","sponsor":"Azidus Brasil","startDate":"2025-02","conditions":["Covid 19","Influenza"],"enrollment":340,"completionDate":"2027-06"},{"nctId":"NCT04489381","phase":"PHASE3","title":"Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection","status":"TERMINATED","sponsor":"Romark Laboratories L.C.","startDate":"2020-08-19","conditions":["Enterovirus","Rhinovirus"],"enrollment":214,"completionDate":"2021-02-02"},{"nctId":"NCT05157243","phase":"PHASE3","title":"Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness","status":"WITHDRAWN","sponsor":"Romark Laboratories L.C.","startDate":"2024-08","conditions":["COVID-19"],"enrollment":0,"completionDate":"2025-05"},{"nctId":"NCT05157269","phase":"PHASE3","title":"Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness","status":"WITHDRAWN","sponsor":"Romark Laboratories L.C.","startDate":"2024-08","conditions":["COVID-19"],"enrollment":0,"completionDate":"2025-03"},{"nctId":"NCT04343248","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","status":"TERMINATED","sponsor":"Romark Laboratories L.C.","startDate":"2020-05-12","conditions":["COVID-19","Viral Respiratory Illnesses"],"enrollment":190,"completionDate":"2021-02-01"},{"nctId":"NCT04359680","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2020-05-13","conditions":["COVID-19","Viral Respiratory Illnesses"],"enrollment":1407,"completionDate":"2021-04-07"},{"nctId":"NCT04486313","phase":"PHASE3","title":"Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2020-08-13","conditions":["COVID-19"],"enrollment":935,"completionDate":"2021-02-08"},{"nctId":"NCT02165813","phase":"PHASE2,PHASE3","title":"Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children","status":"TERMINATED","sponsor":"Telethon Kids Institute","startDate":"2014-11","conditions":["Gastroenteritis"],"enrollment":216,"completionDate":"2021-06-06"},{"nctId":"NCT03905655","phase":"PHASE2","title":"Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2019-10-22","conditions":["Chronic Hepatitis B"],"enrollment":51,"completionDate":"2021-10-11"},{"nctId":"NCT06101420","phase":"PHASE3","title":"Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":["Helicobacter Pylori Eradication"],"enrollment":232,"completionDate":"2023-06-01"},{"nctId":"NCT04103216","phase":"NA","title":"Treatment of Cryptosporidiosis","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2020-02-01","conditions":["Cryptosporidiosis"],"enrollment":64,"completionDate":"2023-08-31"},{"nctId":"NCT01227421","phase":"PHASE2,PHASE3","title":"Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2010-12","conditions":["Influenza"],"enrollment":624,"completionDate":"2011-05"},{"nctId":"NCT06050824","phase":"PHASE4","title":"A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Helwan University","startDate":"2022-07-21","conditions":["H. Pylori Infection"],"enrollment":200,"completionDate":"2023-07-19"},{"nctId":"NCT06049901","phase":"PHASE3","title":"Nitazoxanide in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-03-01","conditions":["Metastatic Colorectal Cancer"],"enrollment":60,"completionDate":"2026-03"},{"nctId":"NCT05680792","phase":"NA","title":"Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers","status":"COMPLETED","sponsor":"Obafemi Awolowo University","startDate":"2020-09-10","conditions":["Drug Interaction"],"enrollment":17,"completionDate":"2023-01-31"},{"nctId":"NCT06010992","phase":"PHASE2","title":"Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-10-01","conditions":["Diabetes Mellitus, Type 2"],"enrollment":70,"completionDate":"2025-01-01"},{"nctId":"NCT05897034","phase":"PHASE2,PHASE3","title":"Combination Therapy Between Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2023-06-20","conditions":["Sexually Transmitted Diseases"],"enrollment":100,"completionDate":"2028-06-20"},{"nctId":"NCT05480878","phase":"PHASE3","title":"Role of Nitazoxanide and Escitalopram in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2022-12-02","conditions":["Rheumatoid Arthritis"],"enrollment":90,"completionDate":"2023-04-01"},{"nctId":"NCT04918927","phase":"PHASE2","title":"Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19","status":"COMPLETED","sponsor":"Coordinación de Investigación en Salud, Mexico","startDate":"2021-10-12","conditions":["Covid19"],"enrollment":120,"completionDate":"2023-03-21"},{"nctId":"NCT03441893","phase":"PHASE1,PHASE2","title":"Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis","status":"UNKNOWN","sponsor":"Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan","startDate":"2015-01-01","conditions":["Ulcerative Colitis","Ulcerative Colitis Exacerbation","Protozoan Infections","Helminth Infection"],"enrollment":300,"completionDate":"2025-12-31"},{"nctId":"NCT05648422","phase":"NA","title":"Effect of the Nutritional Support System on Neuromotor Alterations in Patients With Cerebral Palsy","status":"UNKNOWN","sponsor":"Anahuac University","startDate":"2023-01-16","conditions":["Cerebral Palsy","Spastic","Malnutrition"],"enrollment":144,"completionDate":"2025-01"},{"nctId":"NCT04920838","phase":"PHASE2,PHASE3","title":"Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection","status":"UNKNOWN","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-04-12","conditions":["Covid19","Covid19 Drug Treatment","Severe Acute Respiratory Syndrome Coronavirus 2","SARS-CoV2 Infection"],"enrollment":600,"completionDate":"2023-08"},{"nctId":"NCT04423861","phase":"PHASE3","title":"Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Azidus Brasil","startDate":"2022-06-22","conditions":["covid19"],"enrollment":380,"completionDate":"2023-03"},{"nctId":"NCT05368935","phase":"PHASE1","title":"Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects","status":"COMPLETED","sponsor":"Genfit","startDate":"2022-04-25","conditions":["Renal Impairment","Renal Disease","Kidney Disease"],"enrollment":77,"completionDate":"2022-09-09"},{"nctId":"NCT04435314","phase":"PHASE2","title":"Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19","status":"WITHDRAWN","sponsor":"Azidus Brasil","startDate":"2020-06","conditions":["covid19"],"enrollment":0,"completionDate":"2020-08"},{"nctId":"NCT04348409","phase":"NA","title":"Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2020-05-25","conditions":["COVID-19"],"enrollment":50,"completionDate":"2020-12-31"},{"nctId":"NCT04441398","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients","status":"WITHDRAWN","sponsor":"Azidus Brasil","startDate":"2020-07","conditions":["covid19"],"enrollment":0,"completionDate":"2020-09"},{"nctId":"NCT05116826","phase":"PHASE1","title":"Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients","status":"COMPLETED","sponsor":"Genfit","startDate":"2021-11-05","conditions":["Moderate Hepatic Impairment","Severe Hepatic Impairment","Liver Diseases"],"enrollment":25,"completionDate":"2022-04-13"},{"nctId":"NCT04523090","phase":"PHASE2,PHASE3","title":"Catalysing the Containment of COVID-19","status":"TERMINATED","sponsor":"University of Cape Town","startDate":"2020-08-27","conditions":["COVID-19"],"enrollment":322,"completionDate":"2022-08-12"},{"nctId":"NCT05417815","phase":"","title":"Interest of Nitazoxanide Treatment of Enterocytozoon Bieneusi Intestinal Microsporidiosis","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2022-04-01","conditions":["Microsporidiosis Intestinal"],"enrollment":80,"completionDate":"2022-06-01"},{"nctId":"NCT04563208","phase":"PHASE2","title":"Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-12-09","conditions":["Covid19","SARS-CoV Infection"],"enrollment":80,"completionDate":"2022-02-28"},{"nctId":"NCT03656068","phase":"PHASE2","title":"An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis","status":"COMPLETED","sponsor":"Pinnacle Clinical Research, PLLC","startDate":"2018-12-04","conditions":["Non-alcoholic Steatohepatitis","Fatty Liver","Fibrosis, Liver","Compensated Cirrhosis"],"enrollment":21,"completionDate":"2020-11-25"},{"nctId":"NCT03336619","phase":"PHASE3","title":"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2018-01-17","conditions":["Influenza"],"enrollment":1030,"completionDate":"2019-04-17"},{"nctId":"NCT04561063","phase":"PHASE2","title":"COVID-19 Prophylaxis South Africa (COVER HCW)","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-12-08","conditions":["Covid19","SARS-CoV Infection"],"enrollment":1950,"completionDate":"2022-02-28"},{"nctId":"NCT04605588","phase":"PHASE2","title":"A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-12-02","conditions":["SARS-CoV Infection","Covid19"],"enrollment":7,"completionDate":"2021-02-04"},{"nctId":"NCT03605862","phase":"PHASE3","title":"Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2018-09-11","conditions":["Enterovirus","Rhinovirus"],"enrollment":1756,"completionDate":"2019-02-04"},{"nctId":"NCT02366884","phase":"PHASE2","title":"Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)","status":"UNKNOWN","sponsor":"Dr. Frank Arguello Cancer Clinic","startDate":"2011-07-26","conditions":["Neoplasms"],"enrollment":250,"completionDate":"2023-12-31"},{"nctId":"NCT04459286","phase":"PHASE2","title":"The Nitazoxanide Plus Atazanavir for COVID-19 Study","status":"TERMINATED","sponsor":"Obafemi Awolowo University","startDate":"2020-10-09","conditions":["Covid-19"],"enrollment":57,"completionDate":"2021-05-02"},{"nctId":"NCT05184491","phase":"PHASE4","title":"Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management","status":"UNKNOWN","sponsor":"National Liver Institute, Egypt","startDate":"2021-10-15","conditions":["Helicobacter Pylori"],"enrollment":500,"completionDate":"2022-03-15"},{"nctId":"NCT00991289","phase":"PHASE2","title":"Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-01","conditions":["HIV Infection","Hepatitis C Infection"],"enrollment":68,"completionDate":"2012-01"},{"nctId":"NCT00001081","phase":"PHASE2","title":"A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Cryptosporidiosis","HIV Infections"],"enrollment":60,"completionDate":"1998-09"},{"nctId":"NCT00055107","phase":"PHASE1,PHASE2","title":"Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Cryptosporidiosis"],"enrollment":6,"completionDate":"2006-05"},{"nctId":"NCT01185028","phase":"PHASE1,PHASE2","title":"A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2010-08","conditions":["Hepatitis C Infection","HIV Infection"],"enrollment":8,"completionDate":"2011-10"},{"nctId":"NCT04561219","phase":"PHASE2","title":"Nitazoxanide Therapy for Patients With COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2020-04-19","conditions":["Covid19","Corona Virus Infection","Pneumonia, Viral"],"enrollment":500,"completionDate":"2020-10-02"},{"nctId":"NCT04959786","phase":"PHASE2,PHASE3","title":"MANS-NRIZ Trial for COVID-19 Treatment : Extension Study","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-04-01","conditions":["COVID-19 Pneumonia"],"enrollment":100,"completionDate":"2022-12"},{"nctId":"NCT04788407","phase":"PHASE4","title":"Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts","status":"UNKNOWN","sponsor":"Fundación Huésped","startDate":"2020-12-01","conditions":["Covid19","SARS-CoV-2 Infection","Households Contacts"],"enrollment":456,"completionDate":"2022-04-30"},{"nctId":"NCT03268902","phase":"PHASE2,PHASE3","title":"Early Life Interventions for Childhood Growth and Development In Tanzania","status":"COMPLETED","sponsor":"Haydom Lutheran Hospital","startDate":"2017-09-05","conditions":["Malnutrition","Stunting","Cognitive Development","Enteric Pathogens"],"enrollment":1188,"completionDate":"2020-03-26"},{"nctId":"NCT04341493","phase":"PHASE4","title":"Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19","status":"TERMINATED","sponsor":"Hugo Mendieta Zeron","startDate":"2020-04-06","conditions":["Coronavirus Infection"],"enrollment":44,"completionDate":"2020-12-30"},{"nctId":"NCT04406246","phase":"PHASE4","title":"Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide","status":"COMPLETED","sponsor":"Materno-Perinatal Hospital of the State of Mexico","startDate":"2020-05-21","conditions":["Coronavirus Infection"],"enrollment":150,"completionDate":"2020-12-31"},{"nctId":"NCT04768530","phase":"PHASE2","title":"Nitazoxanide as a New Local Adjunctive to Nonsurgical Treatment of Moderate Periodontitis","status":"COMPLETED","sponsor":"Maha Talaab","startDate":"2019-07-20","conditions":["Periodontitis"],"enrollment":40,"completionDate":"2020-04-30"},{"nctId":"NCT04746937","phase":"PHASE3","title":"Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2021-03","conditions":["Spontaneous Bacterial Peritonitis"],"enrollment":60,"completionDate":"2022-05"},{"nctId":"NCT04729491","phase":"PHASE2,PHASE3","title":"EAT-DUTA AndroCoV Trial","status":"COMPLETED","sponsor":"Corpometria Institute","startDate":"2020-06-30","conditions":["Covid19"],"enrollment":138,"completionDate":"2020-10-07"},{"nctId":"NCT04382846","phase":"PHASE3","title":"Novel Regimens in COVID-19 Treatment","status":"RECRUITING","sponsor":"Tanta University","startDate":"2020-05-08","conditions":["COVID","Corona Virus Infection"],"enrollment":160,"completionDate":"2030-12-01"},{"nctId":"NCT04498936","phase":"PHASE4","title":"Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19","status":"COMPLETED","sponsor":"Assiut University","startDate":"2020-07-15","conditions":["COVID"],"enrollment":240,"completionDate":"2020-10-30"},{"nctId":"NCT04552483","phase":"PHASE2","title":"Effects of Early Use of Nitazoxanide in Patients With COVID-19","status":"COMPLETED","sponsor":"Universidade Federal do Rio de Janeiro","startDate":"2020-06-08","conditions":["Covid19","Coronavirus"],"enrollment":392,"completionDate":"2020-09-05"},{"nctId":"NCT04463264","phase":"PHASE2,PHASE3","title":"Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)","status":"UNKNOWN","sponsor":"Laboratorios Roemmers S.A.I.C.F.","startDate":"2020-06-26","conditions":["COVID-19"],"enrollment":135,"completionDate":"2020-12-26"},{"nctId":"NCT04392427","phase":"PHASE3","title":"New Antiviral Drugs for Treatment of COVID-19","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2020-10","conditions":["COVID","Drug Effect"],"enrollment":100,"completionDate":"2022-05"},{"nctId":"NCT02684240","phase":"PHASE2","title":"A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2016-02","conditions":["Tuberculosis"],"enrollment":30,"completionDate":"2018-04-11"},{"nctId":"NCT04415983","phase":"PHASE3","title":"Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children","status":"RECRUITING","sponsor":"Tanta University","startDate":"2020-06-01","conditions":["Helicobacter Pylori Infection"],"enrollment":100,"completionDate":"2030-12-01"},{"nctId":"NCT04361318","phase":"PHASE2,PHASE3","title":"Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-05","conditions":["COVID-19"],"enrollment":100,"completionDate":"2020-12"},{"nctId":"NCT04360356","phase":"PHASE2,PHASE3","title":"Ivermectin and Nitazoxanide Combination Therapy for COVID-19","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2020-05","conditions":["COVID-19"],"enrollment":100,"completionDate":"2020-12"},{"nctId":"NCT04039412","phase":"PHASE4","title":"Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt","status":"COMPLETED","sponsor":"Ayman Magd Eldin Mohammad Sadek","startDate":"2018-06-01","conditions":["Helicobacter Pylori Infection"],"enrollment":330,"completionDate":"2019-06-30"},{"nctId":"NCT04161053","phase":"PHASE3","title":"Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2018-11-01","conditions":["Hepatic Encephalopathy"],"enrollment":60,"completionDate":"2028-12"},{"nctId":"NCT03933709","phase":"NA","title":"Effect of a Nutritional Support System for Improving Gross Motor Function in Cerebral Palsy","status":"COMPLETED","sponsor":"Anahuac University","startDate":"2015-01-12","conditions":["Nutrition Disorder, Child","Gross Motor Development Delay","Neuro: Cerebral Palsy","Diet Modification","Probiotics"],"enrollment":30,"completionDate":"2017-04-07"},{"nctId":"NCT01641341","phase":"PHASE4","title":"Irritable Bowel Syndrome Evaluation and Treatment in Primary Care","status":"COMPLETED","sponsor":"American Academy of Family Physicians","startDate":"2010-11","conditions":["Irritable Bowel Syndrome"],"enrollment":61,"completionDate":"2012-03"},{"nctId":"NCT02057757","phase":"PHASE2","title":"Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-02","conditions":["Severe Acute Respiratory Illness"],"enrollment":260,"completionDate":"2018-01"},{"nctId":"NCT03491995","phase":"PHASE3","title":"A Unique Regimen for Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2018-04-01","conditions":["Helicobacter Infections"],"enrollment":600,"completionDate":"2023-04-01"},{"nctId":"NCT01056380","phase":"PHASE2","title":"Study of Nitazoxanide in Adults With Acute Uncomplicated Influenza","status":"TERMINATED","sponsor":"Romark Laboratories L.C.","startDate":"2010-01","conditions":["Influenza"],"enrollment":79,"completionDate":"2010-12"},{"nctId":"NCT02612922","phase":"PHASE3","title":"Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2015-12","conditions":["Influenza"],"enrollment":325,"completionDate":"2016-09-04"},{"nctId":"NCT01610245","phase":"PHASE3","title":"Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2013-03","conditions":["Influenza"],"enrollment":1941,"completionDate":"2015-04-16"},{"nctId":"NCT02621359","phase":"PHASE3","title":"A Two Week Nitazoxanidebased Quadruple Regimen","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2015-01","conditions":["Dyspepsia"],"enrollment":100,"completionDate":"2022-12"},{"nctId":"NCT00304356","phase":"PHASE3","title":"Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection","status":"COMPLETED","sponsor":"Daniel M. Musher MD","startDate":"2004-01","conditions":["Clostridium Enterocolitis","Pseudomembranous Colitis"],"enrollment":22,"completionDate":"2007-01"},{"nctId":"NCT02452905","phase":"PHASE2","title":"Finding Better Treatment of Bronchiolitis: A Clinical Trial of Oral Nitazoxanide for the Treatment of Bronchiolitis in Infants Presenting to Hospital Emergency Departments","status":"WITHDRAWN","sponsor":"Telethon Kids Institute","startDate":"2016-12","conditions":["Bronchiolitis"],"enrollment":0,"completionDate":"2018-07"},{"nctId":"NCT02464124","phase":"PHASE2,PHASE3","title":"Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2016-01","conditions":["Encephalopathy, Hepatic"],"enrollment":120,"completionDate":"2017-12"},{"nctId":"NCT02422706","phase":"PHASE3","title":"Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2015-01","conditions":["Helicobacter-associated Gastritis"],"enrollment":120,"completionDate":"2018-12"},{"nctId":"NCT00304889","phase":"","title":"Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis","status":"COMPLETED","sponsor":"Michael E. DeBakey VA Medical Center","startDate":"2006-01","conditions":["Clostridium Enterocolitis","Pseudomembranous Colitis","Antibiotic-Associated Colitis"],"enrollment":52,"completionDate":"2008-01"},{"nctId":"NCT00384527","phase":"PHASE3","title":"Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease","status":"TERMINATED","sponsor":"Romark Laboratories L.C.","startDate":"2006-12","conditions":["Clostridium Infections"],"enrollment":50,"completionDate":"2007-10"},{"nctId":"NCT01529073","phase":"PHASE2","title":"Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection","status":"UNKNOWN","sponsor":"Juan Macías","startDate":"2012-02","conditions":["HCV Coinfection","HIV Infection"],"enrollment":45,"completionDate":"2015-02"},{"nctId":"NCT02334163","phase":"PHASE2","title":"The Effects of Nitazoxanide in Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2014-12","conditions":["Hepatic Encephalopathy"],"enrollment":36,"completionDate":"2015-04"},{"nctId":"NCT01197157","phase":"PHASE2,PHASE3","title":"Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients","status":"COMPLETED","sponsor":"National Liver Institute, Egypt","startDate":"2010-09","conditions":["Hepatitis C"],"enrollment":200,"completionDate":"2014-04"},{"nctId":"NCT01135628","phase":"NA","title":"Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy","status":"COMPLETED","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2010-08","conditions":["Hepatic Cirrhosis","Minimal Hepatic Encephalopathy"],"enrollment":60,"completionDate":"2014-07"},{"nctId":"NCT00495391","phase":"PHASE2","title":"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2007-07","conditions":["Chronic Hepatitis C"],"enrollment":64,"completionDate":"2010-02"},{"nctId":"NCT00637923","phase":"PHASE2","title":"Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2008-03","conditions":["Chronic Hepatitis C"],"enrollment":112,"completionDate":"2010-04"},{"nctId":"NCT01770483","phase":"PHASE4","title":"The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2011-07","conditions":["Hepatitis C, Chronic","DIABETES MELLITUS Type 2"],"enrollment":66,"completionDate":"2013-03"},{"nctId":"NCT01896609","phase":"PHASE4","title":"Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2013-06","conditions":["Chronic Hepatitis c"],"enrollment":300,"completionDate":"2015-06"},{"nctId":"NCT01276756","phase":"PHASE2,PHASE3","title":"Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)","status":"COMPLETED","sponsor":"Cairo University","startDate":"2010-12","conditions":["Chronic Hepatitis c"],"enrollment":100,"completionDate":"2012-11"},{"nctId":"NCT01074203","phase":"PHASE1","title":"A Pilot Study to Examine the Role of Nitazoxanide to Prevent Recurrence of Hepatitis C After Transplantation","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2009-02","conditions":["Hepatitis C Recurrence"],"enrollment":8,"completionDate":"2011-01"},{"nctId":"NCT00302640","phase":"PHASE2,PHASE3","title":"Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in Children","status":"COMPLETED","sponsor":"Romark Laboratories L.C.","startDate":"2005-02","conditions":["Rotavirus Infection","Adenoviridae Infection","Norovirus Infection"],"enrollment":50,"completionDate":"2005-09"},{"nctId":"NCT00130390","phase":"PHASE2","title":"Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease","status":"TERMINATED","sponsor":"Romark Laboratories L.C.","startDate":"2005-08","conditions":["Crohn's Disease"],"enrollment":98,"completionDate":"2008-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Powder, Tablet","formulations":[{"form":"POWDER, FOR SUSPENSION","route":"ORAL","productName":"Alinia"},{"form":"TABLET","route":"ORAL","productName":"Alinia"},{"form":"TABLET","route":"ORAL","productName":"N/A"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Nitazoxanide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148784","MMSL":"17040","NDDF":"006303","UNII":"SOA12P041N","VUID":"4021365","CHEBI":"CHEBI:94807","VANDF":"4021365","INN_ID":"5007","RXNORM":"31819","UMLSCUI":"C0068788","chemblId":"CHEMBL1401","ChEMBL_ID":"CHEMBL1401","KEGG_DRUG":"D02486","DRUGBANK_ID":"DB00507","PDB_CHEM_ID":"NTI","PUBCHEM_CID":"41684","SNOMEDCT_US":"407148001","MESH_SUPPLEMENTAL_RECORD_UI":"C041747"},"formularyStatus":[],"originalProduct":{"form":"POWDER, FOR SUSPENSION","route":"ORAL","company":"Romark Laboratories, L.C.","brandName":"Alinia","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"2002-","companyName":"Romark","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"70%"},"publicationCount":1094,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"P01AX11","allCodes":["P01AX11"]},"biosimilarFilings":[],"originalDeveloper":"Romark","recentPublications":[{"date":"2026 Mar 7","pmid":"41901747","title":"Promising Drug Repurposing Candidates Targeting Free-Living Amoebae: A Systematic and Critical Review of Laboratory-Based Evidence.","journal":"Pathogens (Basel, Switzerland)"},{"date":"2026 Mar 26","pmid":"41888548","title":"Proteasome inhibition promotes Foxn1 expression in thymic epithelial cells and induces thymic regeneration in mice.","journal":"Cell death and differentiation"},{"date":"2026 Mar 27","pmid":"41888416","title":"Modulation of mTOR, NLRP3, and Nrf2/HO-1 signaling by atorvastatin and nitazoxanide in experimental ulcerative colitis.","journal":"Naunyn-Schmiedeberg's archives of pharmacology"},{"date":"2025","pmid":"41867367","title":"Nitazoxanide reduced inflammatory markers and mitochondrial changes in human retinal endothelial cells grown in high glucose.","journal":"Molecular vision"},{"date":"2025 Dec 1","pmid":"41823635","title":"Chronic persistent Norovirus in the immune-compromised host.","journal":"Current opinion in infectious diseases"}],"companionDiagnostics":[],"genericManufacturers":3,"_genericFilersChecked":true,"genericManufacturerList":["Ani Pharms","Annora Pharma","Rising"],"status":"approved","companyName":"Romark","companyId":"romark","modality":"Small molecule","firstApprovalDate":"2002","aiSummary":"","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-11-22T00:00:00.000Z","mah":"ROMARK","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-11-27T00:00:00.000Z","mah":"RISING","brand_name_local":null,"application_number":"ANDA213820"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-02-03T00:00:00.000Z","mah":"ANI PHARMS","brand_name_local":null,"application_number":"ANDA214844"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-15T00:00:00.000Z","mah":"ANNORA PHARMA","brand_name_local":null,"application_number":"ANDA218701"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:08:56.437060+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}